New research that uncovers the mechanism behind the newest generation of cancer drugs is opening the door for better targeted therapy. PARP inhibitors are molecular targeted cancer drugs used to treat women with ovarian cancer who have the BRCA1 and BRCA2 gene mutations. The drugs are showing promise in late-stage clinical trials for breast cancer, prostate cancer and pancreatic cancer.
Related Posts
Order Antibiotics online
June 8, 2024Buying antibiotics online
June 8, 2024How do antibiotics work?
June 8, 2024Flagyl: a beacon of hope in the fight against trichomoniasis
February 17, 2024Metronidazole for bacterial infection
February 1, 2023